N47: Spiritual needs of patients with IBD: preliminary results of a pilot studyECCO'24Year: 2024
Authors: Starnella, G.(1);Rosato, I.(1);Canova, C.(1);Savarino, E.V.(2);Zingone, F.(2);Barberio, B.(2);Lorenzon, G.(2);Gregori, D.(1);Comoretto, R.I.(3);MartinatoRN PhD, M.(1)*;
(1)Unit of Biostatistics- Epidemiology and Public Health- University of Padova, Department of Cardiac- Thoracic- Vascular Sciences and Public Health, Padova, Italy;(2)Gastroenterology Unit- University of Padova, Department of Surgery- Oncology and Gastroenterology, Padova, Italy;(3)University of Torino, Department of Sciences of Public Health and Pediatrics, Torino, Italy;
N48: Exploring & evaluating the benefits of initiating an IBD Transition clinicECCO'24Year: 2024
Authors: Scott, G.(1)*;
(1)East Kent Hospitals University Foundation Trust, Gastroenterology - IBD, Ramsgate, United Kingdom;
OP01: PROFILE: a multi-centre, randomised, open-label, biomarker-stratified clinical trial of treatment strategies for patients with newly-diagnosed Crohn’s diseaseECCO'24Year: 2024
Authors: Noor, N.(1,2)*;Lee, J.(3,4);Bond, S.(5,6);Dowling, F.(5);Brezina, B.(1);Patel, K.(7);Ahmad, T.(8,9);Banim, P.(10);Cooney, R.(11);De La Revilla Negro, J.(1);de Silva , S.(12);Din, S.(13);Durai, D.(14);Gordon, J.(15);Irving, P.(16);Johnson, M.(17);Kent, A.(18);Kok, K.B.(19);Moran, G.(20);Patel, P.(21);Probert, C.(22,23);Raine, T.(1);Saich, R.(24);Seward, A.(7);Sharpstone, D.(25);Smith, M.(26);Subramanian, S.(1);Upponi, S.(27);Wiles, A.(28);van den Brink, G.(29,30);Vermeire, S.(31);Jairath, V.(32);D@E@Haens, G.(33);McKinney, E.(2,34,35);Lyons, P.(2,34,35);Lindsay, J.(19);Kennedy, N.(8);Smith, K.(2,34,35);Parkes, M.(1,2);
(1)Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;(2)University of Cambridge School of Clinical Medicine, Department of Medicine, Cambridge, United Kingdom;(3)The Francis Crick Institute, Genetic Mechanisms of Disease Laboratory, London, United Kingdom;(4)Royal Free Hospital, Department of Gastroenterology- UCL Institute of Liver and Digestive Diseases, London, United Kingdom;(5)Cambridge University Hospitals NHS Foundation Trust, Cambridge Clinical Trials Unit, Cambridge, United Kingdom;(6)University of Cambridge, Medical Research Council Biostatistics Unit, Cambridge, United Kingdom;(7)St George’s Hospital, Department of Gastroenterology, London, United Kingdom;(8)Royal Devon University Healthcare NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;(9)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(10)James Paget University Hospital, Department of Gastroenterology, Great Yarmouth, United Kingdom;(11)University Hospitals Birmingham NHS Foundation Trust, GI Unit, Birmingham, United Kingdom;(12)Dudley Group NHS Foundation Trust, Department of Gastroenterology, Dudley, United Kingdom;(13)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(14)Cardiff and Vale University Health Board- University Hospital Wales, Department of Gastroenterology, Cardiff, United Kingdom;(15)Royal Hampshire County Hospital, Department of Gastroenterology, Winchester, United Kingdom;(16)Guy@E@s and St Thomas@E@ Foundation Trust, Department of Gastroenterology, London, United Kingdom;(17)Luton & Dunstable University Hospital, Department of Gastroenterology, Luton, United Kingdom;(18)King@E@s College Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(19)Barts and The London NHS Trust, Department of Gastroenterology, London, United Kingdom;(20)University of Nottingham and Nottingham University Hospitals, National Institute of Health Research Nottingham Biomedical Research Centre, Nottingham, United Kingdom;(21)Epsom & St Helier University Hospitals, Department of Gastroenterology, Carshalton, United Kingdom;(22)Liverpool University Hospitals NHS Foundation Trust, Department of Gastroenterology, Liverpool, United Kingdom;(23)University of Liverpool, Department of Molecular and Clinical Cancer Medicine- Institute of Systems- Molecular and Integrative Biology, Liverpool, United Kingdom;(24)Basingstoke and North Hampshire Hospital, Department of Gastroenterology, Basingstoke, United Kingdom;(25)West Suffolk Hospital NHS Foundation Trust, Department of Gastroenterology, Bury St Edmunds, United Kingdom;(26)University Hospitals Sussex NHS Foundation Trust, Department of Gastroenterology, Brighton, United Kingdom;(27)Cambridge University Hospitals NHS Foundation Trust, Department of Radiology, Cambridge, United Kingdom;(28)The Queen Elizabeth Hospital King’s Lynn NHS Trust, Department of Gastroenterology, King’s Lynn, United Kingdom;(29)Amsterdam Gastroenterology and Metabolism- Tytgat Institute for Liver and Intestinal Research- Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, United Kingdom;(30)Roche, Roche Innovation Center Basel, Basel, Switzerland;(31)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(32)Western University, Division of Gastroenterology- Department of Medicine, London, Canada;(33)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(34)Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge, United Kingdom;(35)PredictImmune Ltd, Babraham Research Campus, Cambridge, United Kingdom;
OP02: IL23R-CAR-Tregs: creating a therapeutic breakthrough for Crohn’s DiseaseECCO'24Year: 2024
Authors: Cui, Y.(1);Boulakirba, S.(2);David, M.(1);Bouchareychas, L.(1);Rouquier, S.(1);Sajuthi, S.(3);Ayrault, M.(1);Navarin, C.(1);Lafon, A.(1);Lara, G.(1);Menardi, A.(2);Saviane, G.(1);Dumont, C.(2);Abel, T.(1);Fenard, D.(1);Lu, H.(3);de la Rosa, M.(1);Gertner-Dardenne, J.(1)*;
(1)Sangamo Therapeutics, Research, Valbonne, France;(2)Sangamo Therapeutics, Non-clinical development, Valbonne, France;(3)Sangamo Therapeutics, Bioinformatics, Richmond, United States;
OP03: Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trialECCO'24Year: 2024
Authors: Sands, B.E.(1)*;Panaccione, R.(2);D@E@Haens, G.(3);Schreiber, S.(4);DuVall, A.(5);Kierkus, J.(6);Naik, S.(7);Gilder, K.(7);Yun, C.(7);Sandborn, W.J.(7);Walczak, M.(8);Vermeire, S.(9);Rubin, D.T.(10);Peyrin-Biroulet, L.(11,12,13);Danese, S.(14);
(1)Icahn School of Medicine at Mount Sinai Medical Center, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(3)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)University Hospital Schleswig-Holstein- Christian-Albrecht University of Kiel, Department of Internal Medicine I, Kiel, Germany;(5)Tyler Research Institute, Gastroenterology, Tyler, United States;(6)The Children’s Memorial Health Institute, Department of Gastroenterology- Hepatology- Nutritional Disorders and Pediatrics, Warsaw, Poland;(7)Ventyx Biosciences, Clinical Development, San Diego, United States;(8)Clinsante, Clinical Research Centre, Bydgoszcz, Poland;(9)University Hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(10)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(11)Nancy University Hospital, Department of Gastroenterology- INFINY Institute- FHU-CURE, Vandœuvre-lès-Nancy, France;(12)Groupe Hospitalier Privé Ambroise Paré – Hartmann, Paris IBD Center, Neuilly sur Seine, France;(13)University of Lorraine, INSERM- NGERE - Nutrition - Genetics and Exposure to Environmental Risks, Vandœuvre-lès-Nancy, France;(14)IRCCS Ospedale San Raffaele- Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milan, Italy;N/A
OP04: Endoscopic healing in paediatric IBD perpetuates a persistent signature characterized by pathogenic Th17 cells and tissue-associated molecular and microbial drivers of diseaseECCO'24Year: 2024
Authors: Siebert, K.(1);Köhler, N.(2);Faro, T.(1);Matchado, M.(3);Hölz, H.(1);Jarosch, S.(4);Koletzko, S.(1);Ohnmacht, C.(5);List, M.(3);Busch, D.(4);Haller, D.(6);Schwerd, T.(1)*;
(1)LMU Klinikum, Dr. von Hauner Children’s Hospital- Department of Paediatrics, Munich, Germany;(2)Technical University of Munich, LipiTUM- Chair of Experimental Bioinformatics, Freising, Germany;(3)Technical University of Munich, Big Data in Biomedicine- Chair of Experimental Bioinformatics, Freising, Germany;(4)Technical University of Munich- Institute for Medical Microbiology, Immunology and Hygiene, Munich, Germany;(5)Technical University of Munich and Helmholtz Center Munich, Center of Allergy and Environment ZAUM- Research Center for Environmental Health, Neuherberg, Germany;(6)Technical University of Munich, Chair of Nutrition and Immunology- ZIEL-Institute for Food and Health, Freising, Germany;
OP05: Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 studyECCO'24Year: 2024
Authors: Ferrante , M.(1)*;Danese , S.(2,3);Chen , M.(4);D@E@Haens , G.(5);Ghosh , S.(6);Hisamatsu , T.(7);Jairath , V.(8,9);Kierkus , J.(10);Peyrin-Biroulet , L.(11,12);Siegmund , B.(13);Bragg , S.M.(14);Crandall , W.(14);Hunter Gibble , T.(14);Lin , Z.(14);Ugolini Lopes , M.(14);Morris , N.(14);Carlier , H.(14);Sands , B.(15);
(1)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)University Vita-Salute San Raffaele, Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Italy;(3)IRCCS San Raffaele Hospital, Gastroenterology and Endoscopy, Milan, Italy;(4)First Affiliated Hospital of Sun Yat-Sen University, Division of Gastroenterology, Guangzhou- Guangdong, China;(5)Amsterdam University Medical Center, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands;(6)University College Cork, APC Microbiome Ireland Centre- College of Medicine and Health, Cork, Ireland;(7)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(8)University Hospital, Division of Gastroenterology- Department of Medicine, London- ON, Canada;(9)Western University, Division of Epidemiology and Biostatistics, London- ON, Canada;(10)The Children@E@s Memorial Health Institute, Department of Gastroenterology- Hepatology- Feeding Disorders and Pediatrics, Warsaw, Poland;(11)University of Lorraine- CHRU-Nancy, Department of Gastroenterology, Nancy, France;(12)University of Lorraine, Inserm- NGERE, Nancy, France;(13)Charité - Universitätsmedizin Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(14)Eli Lilly and Company, Immunology, Indianapolis- IN, United States;(15)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- NY, United States;VIVID Study Group
OP06: Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND StudyECCO'24Year: 2024
Authors: Louis , E.(1);Panaccione , R.(2);Parkes , G.(3);Peyrin-Biroulet , L.(4);Ferrante , M.(5);Hisamatsu , T.(6);Siegmund , B.(7);Kalabic , J.(8);Levine , P.(9);Neimark , E.(9);Wallace , K.(9);Chen , S.(9);Cheng , L.(9);Duan , W.R.(9);Armuzzi , A.(10);Biederman , L.(11);Loftus , E.(12);Melmed , G.(13);Schreiber , S.(14)*;
(1)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology Department, Liege, Belgium;(2)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Alberta, Canada;(3)Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(4)University Hospital of Nancy- Lorraine University, Department of Gastroenterology and INSERM U1256- NGERE- Faculty of Medicine, Vandoeuvre, France;(5)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(6)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Mitaka, Japan;(7)Charité-Universitätsmedizin Berlin- Humboldt-Universität zu Berlin and Berlin Institute of Health, Division of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(8)AbbVie Deutschland GmbH & Co. KG, none, Ludwigshafen, Germany;(9)AbbVie, none, North Chicago, United States;(10)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;(11)University Hospital Zurich, Zurich, Zurich, Switzerland;(12)Mayo Clinic College of Medicine and Science, Department of Gastroenterology and Hepatology, Rochester, United States;(13)F. Widjaja Foundation Inflammatory Bowel Disease Institute- Cedars Sinai Medical Center, none, Los Angeles, United States;(14)University Hospital Schleswig-Holstein- Christian Albrechts University, Department Internal Medicine, Kiel, Germany;
OP07: Consistent IBD treatment approaches across South Asian and White ethnicities despite phenotypic variations: a study of 33,157 patients using the IBD BioResourceECCO'24Year: 2024
Authors: Sharmili, B.(1,2)*;Martinez-Gili, L.(1);Alexander, J.(1,2);Mullish, B.(1,2);Perry, R.(1,2);Li, J.(1);Marchesi, J.(1);Parkes, M.(3);Orchard, T.(1,2);Hicks, L.(1,2);Williams, H.(1,2);
(1)Imperial College London, Metabolism- Digestion and Reproduction, London, United Kingdom;(2)Imperial College NHS Healthcare Trust, Gastroenterology and Hepatology, London, United Kingdom;(3)Cambridge University Hospitals NHS Foundation Trust, Gastroenterology and Hepatology, London, United Kingdom;
OP08: Multi-ancestry genome-wide association study of inflammatory bowel disease identifies 125 novel loci and directly implicates new genes in disease susceptibilityECCO'24Year: 2024
Authors: Fachal, L.(1)*;
(1)Wellcome Sanger Institute, Human Genetics, Hinxton- Saffron Walden, United Kingdom;on behalf of the International IBD Genetics Consortium
OP09: Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella studyECCO'24Year: 2024
Authors: Vermeire, S.(1)*;Allegretti, J.R.(2);Kim, H.J.(3);Long, M.D.(4);Leszczyszyn, J.(5);Schreiber, S.(6);Mross, M.R.(7);Kierkus, J.(8);Peeva, E.(9);Vincent, M.S.(9);Shojaee, N.(9);Banfield, C.(10);Banerjee, A.(11);Gale, J.D.(9);Hung, K.E.(12);
(1)KU Leuven, Gastroenterology & Hepatology Department, Leuven, Belgium;(2)Brigham and Women@E@s Hospital, Division of Gastroenterology- Hepatology and Endoscopy, Boston, United States;(3)Kyung Hee University, Department of Gastroentereology, Seoul, Korea- Republic Of;(4)University of North Carolina School of Medicine, Division of Gastroenterology and Hepatology, Chapel Hill, United States;(5)Melita Medical, Department of Gastroenterology, Wrocław, Poland;(6)University Hospital Schleswig-Holstein, Department Medicine I, Kiel, Germany;(7)Gastroenterologische Spezialpraxis, Department of Gastroenterology, Berlin, Germany;(8)The Children@E@s Memorial Health Institute, Department of Gastroenterology- Hepatology- Feeding Disorders- and Paediatrics, Warsaw, Poland;(9)Pfizer Inc., Inflammation and Immunology Research Unit, Cambridge, United States;(10)Pfizer Inc., Clinical Pharmacology, Cambridge, United States;(11)Pfizer Inc., Statistics, Cambridge, United States;(12)Pfizer Inc., Inflammatory Bowel Disease/Gastroenterology, Cambridge, United States;
OP10: Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extensionECCO'24Year: 2024
Authors: D@E@Haens, G.(1)*;Louis, E.(2);Loftus Jr., E.V.(3);Regueiro, M.(4);Jairath, V.(5);Magro, F.(6,7,8);Nakase, H.(9);Dubcenco, E.(10);Lacerda, A.P.(10);Feng, T.(10);Duncan, B.(10);Wang, T.(10);Ford, S.(10);Anyanwu, S.I.(10);Blumenstein, I.(11);
(1)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)University Hospital CHU of Liège, Department of Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(3)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(4)Cleveland Clinic Foundation, Department of Gastroenterology and Hepatology, Cleveland, United States;(5)Western University, Department of Medicine, London, Canada;(6)University of Porto, Unit of Pharmacology and Therapeutics- Department of Biomedicine- Faculty of Medicine, Porto, Portugal;(7)University of Porto, CINTESIS@RISE- Faculty of Medicine, Porto, Portugal;(8)São João University Hospital Center, Department of Gastroenterology, Porto, Portugal;(9)Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan;(10)AbbVie, Inc., North Chicago, United States;(11)Goethe-University Hospital, Department of Internal Medicine 1, Frankfurt, Germany;
OP11: Exploring the potential clinical utility of NUDT15 pharmacogenetic testing in clinical practice: a ‘focused reverse phenotyping’ study in the UK IBD BioresourceECCO'24Year: 2024
Authors: Roberts , C.(1,2)*;Sazonovs , A.(3);Smith , R.(1,2);Bishara , M.(1,2);Lin , S.(1);Neil , C.(1);Bewshea , C.(1);Warden , S.(4);Pele , L.(4);Cocking , L.(4);Goodhand , J.(1,2);Kennedy , N.(1,2);Parkes , M.(4,5);Ahmad , T.(1,2);
(1)Exeter IBD and Pharmacogenetics Research Group, Gastroenterology, Exeter, United Kingdom;(2)Royal Devon University Healthcare NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(3)Sanger Institute, Anderson Research Group, Cambridge, United Kingdom;(4)NIHR IBD BioResource, NIHR IBD BioResource, Cambridge, United Kingdom;(5)Cambridge University Hospitals NHS Foundation Trust, Gastroenterology, Cambridge, United Kingdom;UK Inflammatory Bowel Disease Pharmacogenetics Study Group
OP12: Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trialECCO'24Year: 2024
Authors: Travis, S.(1)*;Hisamatsu, T.(2);Fischer, M.(3);Dubinsky, M.(4);Jairath, V.(5);Chen, M.(6);Ferrante, M.(7);Peyrin-Biroulet, L.(8);Siegmund, B.(9);Hunter Gibble, T.(10);Lin, Z.(11);Protic, M.(10);Morris, N.(11);Ghosh, S.(12);
(1)University of Oxford, Kennedy Institute and Translational Gastroenterology Unit, Oxford, United Kingdom;(2)Kyorin University Hospital, Gastroenterology and Hepatology, Tokyo, Japan;(3)Indiana University, Division of Gastroenterology, Indianapolis, United States;(4)Icahn School of Medicine at Mt Sinai, Pediatrics and Medicine, New York, United States;(5)Western University, Division of Gastroenterology, London, Canada;(6)The First Affiliated Hospital of Sun Yat-sen University, Gastroenterology and Hepatology, Guangzhou, China;(7)Leuven University Hospital, Gastroenterology and Hepatology, Leuven, Belgium;(8)University of Lorraine, Gastroenterology, Nancy, France;(9)Charite-Universitatsmedizin, Infectiology and Rheumatology, Berlin, Germany;(10)Eli Lilly and Company, Immunology, Indianapolis, United States;(11)Eli Lilly and Company, Statistics, Indianapolis, United States;(12)National University of Ireland, College of Medicine and Health, Cork, Ireland;
OP13: Anti-integrin ⍺vβ6 autoantibodies are increased in PSC-IBD and correlate with liver disease severityECCO'24Year: 2024
Authors: Bloemen, H.(1)*;Livanos, A.(2);Martins, A.(3);Tankelevich, M.(1);Herb, J.(4);Cho, J.(4);Santos, A.(5);Bravo, A.C.(6);Petralia, F.(7);Colombel, J.F.(8);Schiano, T.(9);Torres, J.(10);Levy, C.(11);Mehandru, S.(2);
(1)Icahn School of Medicine at Mount Sinai, Precision Institute of Immunology, New York, United States;(2)Icahn School of Medicine at Mount Sinai, Precision Institute of Immunology and Division of Gastroenterology, New York, United States;(3)University of Miami Miller School of Medicine, Schiff Center for Liver Diseases, Miami, United States;(4)Icahn School of Medicine at Mount Sinai, The Charles Bronfman Institute for Personalized Medicine, New York, United States;(5)Universidade de Lisboa, Faculdade de Farmácia, Lisbon, Portugal;(6)Hospital Beatriz Ângelo, Division of Gastroenterology, Loures, Portugal;(7)Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York, United States;(8)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(9)Icahn School of Medicine at Mount Sinai, Recanati/Miller Transplantation Institute- Division of Liver Diseases- Department of Medicine, New York, United States;(10)Hospital Beatriz Ângelo/University of Lisbon/Hospital da Luz/Icahn School of Medicine at Mount Sinai NY, Division of Gastroenterology, Loures/Lisbon/New York, Portugal;(11)University of Miami Miller School of Medicine, Schiff Center for Liver Diseases/Division of Digestive Health and liver Diseases, Miami, United States;
OP14: Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative ColitisECCO'24Year: 2024
Authors: Hart, A.(1)*;Martín-Arranz, M.D.(2);Laharie, D.(3);Matsuoka, K.(4);Dhesi, E.(5);Redondo, I.(5);Baygani, S.(5);Zaremba-Pechmann, L.(6);Samaan, K.(5);Navabi, S.(7);
(1)St Mark@E@s Hospital & Imperial College, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(2)Hospital La Paz Institute for Health Research, Department of Gastroenterology, Madrid, Spain;(3)Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux- Hôpital Haut-Lévêque, Bordeaux, France;(4)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Sakura, Japan;(5)Eli Lilly and Company, Eli Lilly and Company, Indianapolis, United States;(6)HaaPACS GmBH, Statistics, Schriesheim, Germany;(7)United Medical Doctors, Gastroenterology- Hepatology and Obesity Medicine, Long Beach- California, United States;
OP15: High-definition white light endoscopy with segmental re-inspection is non-inferior compared to dye-based chromoendoscopy in Inflammatory Bowel Disease: the randomized controlled HELIOS trialECCO'24Year: 2024
Authors: Te Groen, M.(1)*;Wijnands, A.(2);Den Broeder, N.(3);de Jong, D.(1);Van Dop, W.(1);Duijvestein, M.(1);Fidder, H.(4);Van Schaik, F.(2);Hirdes, M.(2);Van der Meulen, A.(5);Maljaars, J.(5);Voorneveld, P.(5);de Boer, N.(6);Peters, C.(6);Oldenburg, B.(2);Hoentjen, F.(7);
(1)Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Utrecht University Medical Center, Gastroenterology and Hepatology, Utrecht, The Netherlands;(3)Maartens Kliniek, Reumatology, Nijmegen, The Netherlands;(4)Utrecht University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(5)Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, The Netherlands;(6)Amsterdam University Medical Centers, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;
OP16: A novel artificial intelligence-assisted Image Enhanced Endoscopy assesses accurately @D@vascular-healing@D@ and predicts long-term clinical relapse in patients with ulcerative colitis: a prospective cohort study.ECCO'24Year: 2024
Authors: Maeda, Y.(1,2)*;Kudo, S.E.(1);Kuroki, T.(1);Masashi , M.(1);Ogata, N.(1);Miyachi, H.(1);Baba, T.(1);Nemoto, T.(1);Ohtsuka, K.(3);Iacucci, M.(2);
(1)Showa University Northern Yokohama Hospital, Digestive Disease Center, Yokohama, Japan;(2)University College Cork, APC Microbiome Ireland- College of Medicine and Health, Cork, Ireland;(3)Tokyo Medical and Dental University- Medical Hospital, Department of Endoscopy, Tokyo, Japan;
OP17: IBD ulcers are characterized by bioactive interleukin-1 and transcriptomic hallmarks of stromal cell state reprogrammingECCO'24Year: 2024
Authors: Mitsialis, V.(1)*;Losa, M.(2);Field, M.(2);Collen, L.(2);Barends, J.(2);Ringel, A.(1);Bresnahan, M.(2);Yang, J.(2);Tumminkatti, R.(2);Sveen, M.(2);Bearup, R.(2);Kotlarz, D.(3);Klein, C.(3);Argmann, C.(4);Schadt, E.(4);Muise, A.(5);Thiagarajah, J.(2);Eran, A.(2);Horwitz, B.(6);Snapper, S.(2);
(1)Boston Children@E@s Hospital and Brigham and Women@E@s Hospital, Gastroenterology/Pediatrics/Medicine, Boston, United States;(2)Boston Children@E@s Hospital, Gastroenterology/Pediatrics, Boston, United States;(3)Ludwig-Maximilians-Universität Munich, Pediatrics, Munich, Germany;(4)Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, New York City, United States;(5)The Hospital for Sick Children and University of Toronto, Pediatrics and Biochemistry, Toronto, Canada;(6)Boston Children@E@s Hospital, Emergency Medicine/Pediatrics, Boston, United States;
OP18: Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn’s Disease: results from the global ADMIRE-CD II phase 3 studyECCO'24Year: 2024
Authors: Serclova, Z.(1)*;Garcia-Olmo, D.(2);Chen, S.T.(3);Wexner, S.(4);Panés, J.(5);Wu, C.(6);Fleshner, P.(7);Zhang, B.(8);Colombel, J.F.(9);Song, M.(10);McKay, C.(11);Nazarey, P.(12);Wright, E.(13);Raffals, L.(14);
(1)NH Hospital- Horovice- ISCARE, Surgical Department, Prague, Czech Republic;(2)Fundacion Jiménez Díaz University Hospital- UAM, Department of Surgery, Madrid, Spain;(3)Takeda Pharmaceuticals USA- Inc.-, Clinical Science, Cambridge- MA, United States;(4)Cleveland Clinic- Weston Hospital, Colorectal Surgery, Weston- FL, United States;(5)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Inflammatory Bowel Disease Unit, Barcelona, Spain;(6)Takeda Pharmaceuticals USA- Inc., Statistics, Cambridge MA, United States;(7)Cedars-Sinai Medical Center, Colorectal Surgery Research, Los Angeles CA, United States;(8)Takeda Pharmaceuticals USA- Inc., GI Medical Safety, Cambridge MA, United States;(9)Icahn School of Medicine, Gastroenterology, New York NY, United States;(10)Takeda Pharmaceuticals USA- Inc., Clinical Science, Cambridge MA, United States;(11)Takeda Pharmaceuticals USA- Inc., Global Evidence & Outcomes, Cambridge MA, United States;(12)Takeda Pharmaceuticals USA- Inc., US Medical- Rare GI-CPF, Cambridge MA, United States;(13)Takeda Pharmaceuticals USA- Inc., Global Medical Affairs, Cambridge MA, United States;(14)Mayo Clinic, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Rochester MN, United States;